Monsanto rejects Bayer’s $62 billion offer

pharmafile | May 25, 2016 | News story | Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto 

World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) saying the deal was incomplete and financially inadequate, but added it was open to further talks.

Monsanto shares ended up over 3% Tuesday on the New York Stock Exchange.

Monsanto’s chief executive Hugh Grant, said: “We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer’s business. However, the current proposal significantly undervalues our company and also does not adequately address or provide reassurance for some of the potential financing and regulatory execution risks related to the acquisition.”

On Monday, the pharma and crop sciences giant, Bayer, made an unsolicited $62 billion all-cash offer for Monsanto in a deal that could potentially create the largest agricultural supplier on the planet. 

Werner Baumann, chief executive of Bayer, said: “Together we would draw on the collective expertise of both companies to build a leading agriculture player with exceptional innovation capabilities to the benefit of farmers, consumers, our employees and the communities in which we operate.” 

The combined entity would have an imposing position in the global markets including the US, Europe and Asia.

Anjali Shukla

 

Related Content

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

andrei_r_-_shutterstock_1935537274_720

LegoChem and Iksuda expand License Agreement for antibody drug conjugates

Iksuda Therapeutics, a developer of antibody drug conjugates (ADCs), has announced the expansion of the …

Exscientia buys Austrian cancer cell screening company for €50 million

UK-based AI pioneers Exscientia has announced the purchase of rival AI firm Allcyte for €50 …

Latest content